Literature DB >> 7956738

Metabolic fate of [3H]-l-menthol in the rat.

T Yamaguchi1, J Caldwell, P B Farmer.   

Abstract

[3-3H]-l-Menthol was administered by oral gavage to intact and bile duct-cannulated male Fischer 344 rats at a dose level of 500 mg/kg. Excreta were collected for up to 48 hr and metabolites in urine and bile analyzed by TLC, solid phase extraction, GLC, and GC/MS. In intact rats, some 71% of the dose was recovered in 48 hr with approximately equal amounts in urine and feces. Seventy-four percent of the dose was recovered from bile duct-cannulated rats, with 67% in the bile and 7% in the urine. The major biliary metabolite was menthol glucuronide, which undergoes enterohepatic circulation. The urinary metabolites resulted from hydroxylation at the C-7 methyl group at C-8 and C-9 in the isopropyl moiety, resulting in a series of mono- and dihydroxy-menthols and carboxylic acids, some of which are excreted in part as glucuronic acid conjugates. In addition, menthol glucuronide is found in the urine. The results have enabled the construction of a metabolic map for menthol in the rat that provides the basis for structure-metabolism relationships describing the fate of numerous menthol congeners of flavor importance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7956738

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  12 in total

Review 1.  Pharmacological perspectives on the detoxification of plant secondary metabolites: implications for ingestive behavior of herbivores.

Authors:  Stuart McLean; Alan J Duncan
Journal:  J Chem Ecol       Date:  2006-05-23       Impact factor: 2.626

2.  Effect of menthol on the pharmacokinetics and pharmacodynamics of felodipine in healthy subjects.

Authors:  Ayse Gelal; Dilara Balkan; Deniz Ozzeybek; Yusuf C Kaplan; Selma Gurler; Hulya Guven; Neal L Benowitz
Journal:  Eur J Clin Pharmacol       Date:  2004-12-11       Impact factor: 2.953

Review 3.  African-American smokers and cancers of the lung and of the upper respiratory and digestive tracts. Is menthol part of the puzzle?

Authors:  T L Richardson
Journal:  West J Med       Date:  1997-03

4.  Use of Entero-Test, a simple approach for non-invasive clinical evaluation of the biliary disposition of drugs.

Authors:  William J Guiney; Claire Beaumont; Steve R Thomas; Darren C Robertson; Simon M McHugh; Annelize Koch; Duncan Richards
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

5.  Menthol attenuates respiratory irritation responses to multiple cigarette smoke irritants.

Authors:  Daniel N Willis; Boyi Liu; Michael A Ha; Sven-Eric Jordt; John B Morris
Journal:  FASEB J       Date:  2011-09-08       Impact factor: 5.191

Review 6.  Review article: the physiological effects and safety of peppermint oil and its efficacy in irritable bowel syndrome and other functional disorders.

Authors:  B P Chumpitazi; G L Kearns; R J Shulman
Journal:  Aliment Pharmacol Ther       Date:  2018-01-26       Impact factor: 8.171

7.  Influence of menthol on caffeine disposition and pharmacodynamics in healthy female volunteers.

Authors:  Ayse Gelal; Hulya Guven; Dilara Balkan; Levent Artok; Neal L Benowitz
Journal:  Eur J Clin Pharmacol       Date:  2003-08-14       Impact factor: 2.953

8.  Randomised trial: Peppermint oil (menthol) pharmacokinetics in children and effects on gut motility in children with functional abdominal pain.

Authors:  Robert J Shulman; Bruno P Chumpitazi; Susan M Abdel-Rahman; Uttam Garg; Salma Musaad; Gregory L Kearns
Journal:  Br J Clin Pharmacol       Date:  2021-10-19       Impact factor: 4.335

9.  Systemic exposure to menthol following administration of peppermint oil to paediatric patients.

Authors:  Gregory L Kearns; Bruno Pedro Chumpitazi; Susan M Abdel-Rahman; Uttam Garg; Robert J Shulman
Journal:  BMJ Open       Date:  2015-08-12       Impact factor: 2.692

10.  Preclinical disposition of MGS0274 besylate, a prodrug of a potent group II metabotropic glutamate receptor agonist MGS0008 for the treatment of schizophrenia.

Authors:  Kohnosuke Kinoshita; Motoki Ochi; Katsuya Iwata; Misako Fukasawa; Jun-Ichi Yamaguchi
Journal:  Pharmacol Res Perspect       Date:  2019-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.